John E. Morley

John E. Morley

Auto-generated profile, based on publicly available information

John E. Morley

Saint Louis University

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
JMJohn E. Morley
John E. Morley
BVBruno Vellas
Bruno Vellas
GKG. Abellan van Kan
G. Abellan van Kan
SAStefan D. Anker
Stefan D. Anker
JBJuergen M. Bauer
Juergen M. Bauer
JWJeremy Walston
Jeremy Walston

1 August 2012 in The Journal of nutrition, health and aging
Verified
Journal Article
Open access
PDF file
JMJohn E. Morley
John E. Morley
TMT. K. Malmstrom
T. K. Malmstrom
DMD. K. Miller
D. K. Miller
Objective To validate the FRAIL scale. Design Longitudinal study. Setting Community. Participants Representative sample of African Americans age 49 to 65 years at onset of study. Measurements The 5-item FRAIL scale (Fatigue, Resistance, Ambulation, Illnesses, & Loss of Weight), at baseline and activities of daily living (ADLs), instrumental activities of daily living (IADLs), mortality, short physical performance battery (SPPB), gait speed, one-leg stand, grip strength and injurious falls at baseline and 9 years. Blood tests for CRP, SIL6R, STNFR1, STNFR2 and 25 (OH) vitamin D at baseline. Results Cross-sectionally the FRAIL scale correlated significantly with IADL difficulties, SPPB, grip strength and one-leg stand among participants with no baseline ADL difficulties (N=703) and those outcomes plus gait speed in those with no baseline ADL dependencies (N=883). TNFR1 was increased in pre-frail and frail subjects and CRP in some subgroups. Longitudinally (N=423 with no baseline ADL difficulties or N=528 with no baseline ADL dependencies), and adjusted for the baseline value for each outcome, being pre-frail at baseline significantly predicted future ADL difficulties, worse one-leg stand scores, and mortality in both groups, plus IADL difficulties in the dependence-excluded group. Being frail at baseline significantly predicted future ADL difficulties, IADL difficulties, and mortality in both groups, plus worse SPPB in the dependence-excluded group. Conclusion This study has validated the FRAIL scale in a late middle-aged African American population. This simple 5-question scale is an excellent screening test for clinicians to identify frail persons at risk of developing disability as well as decline in health functioning and mortality.

1 July 2011 in Journal of the American Medical Directors Association
Verified
Journal Article
Closed access
JMJohn E. Morley
John E. Morley
AAAngela Marie Abbatecola
Angela Marie Abbatecola
JAJosep M. Argiles
Josep M. Argiles
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos
JBJuergen Bauer
Juergen Bauer
SAStefan D. Anker
Stefan D. Anker

17 October 2016 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
SAStefan D. Anker
Stefan D. Anker
JMJohn E. Morley
John E. Morley
SHStephan von Haehling
Stephan von Haehling
The new ICD‐10‐CM (M62.84) code for sarcopenia represents a major step forward in recognizing sarcopenia as a disease. This should lead to an increase in availability of diagnostic tools and the enthusiasm for pharmacological companies to develop drugs for sarcopenia.

15 September 2019 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
JBJuergen Bauer
Juergen Bauer
JMJohn E. Morley
John E. Morley
ASAnnemie M.W.J. Schols
Annemie M.W.J. Schols
LFLuigi Ferrucci
Luigi Ferrucci
ACAlfonso J. Cruz-Jentoft
Alfonso J. Cruz-Jentoft
SAStefan D. Anker
Stefan D. Anker
The term sarcopenia was introduced in 1988. The original definition was a “muscle loss” of the appendicular muscle mass in the older people as measured by dual energy x‐ray absorptiometry (DXA). In 2010, the definition was altered to be low muscle mass together with low muscle function and this was agreed upon as reported in a number of consensus papers. The Society of Sarcopenia, Cachexia and Wasting Disorders supports the recommendations of more recent consensus conferences, i.e. that rapid screening, such as with the SARC‐F questionnaire, should be utilized with a formal diagnosis being made by measuring grip strength or chair stand together with DXA estimation of appendicular muscle mass (indexed for height2). Assessments of the utility of ultrasound and creatine dilution techniques are ongoing. Use of ultrasound may not be easily reproducible. Primary sarcopenia is aging associated (mediated) loss of muscle mass. Secondary sarcopenia (or disease‐related sarcopenia) has predominantly focused on loss of muscle mass without the emphasis on muscle function. Diseases that can cause muscle wasting (i.e. secondary sarcopenia) include malignant cancer, COPD, heart failure, and renal failure and others. Management of sarcopenia should consist of resistance exercise in combination with a protein intake of 1 to 1.5 g/kg/day. There is insufficient evidence that vitamin D and anabolic steroids are beneficial. These recommendations apply to both primary (age‐related) sarcopenia and secondary (disease related) sarcopenia. Secondary sarcopenia also needs appropriate treatment of the underlying disease. It is important that primary care health professionals become aware of and make the diagnosis of age‐related and disease‐related sarcopenia. It is important to address the risk factors for sarcopenia, particularly low physical activity and sedentary behavior in the general population, using a life‐long approach. There is a need for more clinical research into the appropriate measurement for muscle mass and the management of sarcopenia. Accordingly, this position statement provides recommendations on the management of sarcopenia and how to progress the knowledge and recognition of sarcopenia.

1 April 2006 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
JMJohn E Morley
John E Morley
DTDavid R Thomas
David R Thomas
MWMargaret-Mary G Wilson
Margaret-Mary G Wilson
Cachexia causes weight loss and increased mortality. It affects more than 5 million persons in the United States. Other causes of weight loss include anorexia, sarcopenia, and dehydration. The pathophysiology of cachexia is reviewed in this article. The major cause appears to be cytokine excess. Other potential mediators include testosterone and insulin-like growth factor I deficiency, excess myostatin, and excess glucocorticoids. Numerous diseases can result in cachexia, each by a slightly different mechanism. Both nutritional support and orexigenic agents play a role in the management of cachexia.